Cefoperazone-sulbactam for treatment of intra-abdominal infections: Results from a randomized, parallel group study in India

Surgical Infections

Volumn 9, Issue 3, 2008, Pages 367-376

  Chandra, Abhijit ^a   Dhar, Puneet ^b   Dharap, Satish ^c   Goel, Amitabh ^d   Gupta, Rajesh ^e   Hardikar, Jayprakash V ^f   Kapoor, Vinay K ^g   Mathur, Ashok K ^h   Modi, Pankaj ⁱ   Narwaria, Mahendra ^j   Ramesh, Mayakonda K ^k   Ramesh, Hariharan ^l   Sastry, R A ^m   Shah, Shashank ⁿ   Virk, Satpalsingh ^o   Sudheer, Otivilvayoth V ^b   Sreevathsa, Maddibande R ^p   Varshney, Subodh ^q   Kochhar, Puja ^r   Somasundaram, Sanjay ^r   Desai, Chetan ^r   Schou, Manjula ^r   more..

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

^c LOKMANYA TILAK MUNICIPAL MEDICAL COLLEGE AND GENERAL HOSPITAL   (India)

^d CHOITHRAM HOSPITAL AND RESEARCH CENTRE   (India)

^e POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^f KEM HOSPITAL   (India)

^g SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^h SMS MEDICAL COLLEGE   (India)

ⁱ CIVIL HOSPITAL   (India)

^j Shrey Hospital   (India)

^k Victoria Hospital   (India)

^l Lakeshore Hospital   (India)

^m NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

ⁿ Poona Hospital and Research Centre   (India)

^o DAYANAND MEDICAL COLLEGE AND HOSPITAL   (India)

^p M S RAMAIAH MEDICAL COLLEGE   (India)

^q BHOPAL MEMORIAL HOSPITAL AND RESEARCH CENTRE   (India)

^r PFIZER INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFTAZIDIME; MAGNEX; METROGY; METRONIDAZOLE; MIKACIN; SULPERAZON;

ABDOMINAL INFECTION; ADOLESCENT; ADULT; AGED; ARTICLE; BACKACHE; BACTERIUM ISOLATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ESCHERICHIA COLI; FEMALE; FOLLOW UP; HUMAN; INDIA; KLEBSIELLA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MULTICENTER STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ABDOMINAL ABSCESS; ADOLESCENT; ADULT; AGED; AMIKACIN; ANTI-BACTERIAL AGENTS; CEFOPERAZONE; CEFTAZIDIME; CHILD; DRUG THERAPY, COMBINATION; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INDIA; MALE; METRONIDAZOLE; MIDDLE AGED; PERITONITIS; SULBACTAM; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 45749133011     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2007.013     Document Type: Article

References (28)

1. Tellado JM, Wilson SE. Empiric treatment of nosocomial intra-abdominal infections: A focus on the carbapenems. Surg Infect 2005;6:329-343.
2. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: Evidence for the recommendations. Surg Infect 2002;3:175-233.
3. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: An executive summary. Surg Infect 2002;3:161-173.
4. Nichols RL, Muzik AC. Enterococcal infections in surgical patients: The mystery continues. Clin Infect Dis 1992;15:72-76.
5. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003;37:997-1005.
6. File TM Jr. Overview of resistance in the 1990s. Chest 1999;115(3 Suppl):3S-8S.
7. Uma A, Mehta A, Ayyagari A, et al. Prevalence of β-lactamase producing strains among clinical isolates obtained from hospital in-patients across India and comparison of antibacterial susceptibility using discdiffusion method. Hosp Today 2004;IX(1).
8. Jones RN, Mathai D. A comparison of the antimicrobial activity of meropenem and selected broad-spectrum antimicrobials tested against multi-drug resistant gramnegative bacilli including bacteraemic Salmonella spp.: Initial studies for the MYSTIC programme in India. Int J Antimicrob Agents 2002;20:426-431.
9. Sharma R, Sharma CL, Kapoor B. Antibacterial resistance: Current problems and possible solutions. Indian J Med Sci 2005;59:120-129.
10. Indian Antimicrobial Resistance Study Group. Cefpirome: Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against recent clinical isolates from India: A survey of ten medical center laboratories. Diagn Microbiol Infect Dis 2002;44:367-377.
11. Bradford PA. Extended-spectrum beta-lactamases in the 21st Century: Characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-951.
12. Patterson JE. Extended spectrum beta-lactamases: A therapeutic dilemma. Pediatr Infect Dis J 2002;21: 957-959.
13. Perilli M, Dell'Amico E, Segatore B, et al. Molecular characterization of extended-spectrum beta-lactamases produced by nosocomial isolates of Enterobacteriaceae from an Italian nationwide survey. J Clin Microbiol 2002;40:611-614.
14. Graffunder EM, Preston KE, Evans AM, Venezia RA. Risk factors associated with extended-spectrum beta-lactamase-producing organisms at a tertiary care hospital. J Antimicrob Chemother 2005;56:139-145.
15. Flint LM, Gott J, Short L, et al. Serum level monitoring of aminoglycoside antibiotics: Limitations in intensive care unit-related bacterial pneumonia. Arch Surg 1985;120:99-103.
16. Schentag JJ, Cerra FB, Plaut ME. Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients. Antimicrob Agents Chemother 1982;21:721-726.
17. Solomkin JS, Rivera JO, Bjornson, et al. Use of aminoglycoside antibiotics in surgical infections. Contemp Surg 1983;22:69-77.
18. Greenberg RN, Cayavec P, Danko LS, et al. Comparison of cefoperazone plus sulbactam with clindamycin plus gentamicin as treatment for intra-abdominal infections. J Antimicrob Chemother 1994;34: 391-401.
19. Jauregui LE, Appelbaum PC, Fabian TC, et al. A randomized clinical study of cefoperazone and sulbactam versus gentamicin and clindamycin in the treatment of intra-abdominal infections. J Antimicrob Chemother 1990;25:423-433.
20. Kulkarni RA, Kochhar PH, Dargude VA, et al. Patterns of antimicrobial use by surgeons in India. Indian J Surg 2005;67:308-315.
21. Blot S, De Waele JJ. Critical issues in the clinical management of complicated intra-abdominal infections. Drugs 2005;65:1611-1620.
22. Cefobid: US Product information. Pfizer 2003. (Available at www.pfizer.com/pfizer/do/medicines/mn_uspi.jsp#c; accessed January 19, 2007).
23. Magnex (cefoperazone/sulbactam): India Package Insert. Pfizer 2002. (Available at www.pfizerindia. com/products.asp; accessed January 19, 2007).
24. Akyurek N, Bedirli A, Kucuk KC. Randomised comparison of cefoperazone-sulbactam and imipenemcilastatin in the treatment of intraabdominal infections. Br J Surg 1997;84:880-884.
25. Wexler HM, Finegold SM. In vitro activity of cefoperazone plus sulbactam compared with that of other antimicrobial agents against anaerobic bacteria 18. Antimicrob Agents Chemother 1988;32:403-406.
26. Konig C, Simmen HP, Blaser J. Bacterial concentrations in pus and infected peritoneal fluid: Implications for bactericidal activity of antibiotics. J Antimicrob Chemother 1998;42:227-232.
27. Beketov AS, Sidorenko SV, Pisarev VV, Komarov RM. Comparative clinical and epidemiological evaluation of beta-lactam antibiotics in the treatment of intraabdominal infections. Antibiot Khimioter 2003;48(3):34-41.
28. Bailey JA, Virgo KS, DiPrio JT, et al. Aminoglycosides for intra-abdominal infection: Equal to the challenge? Surg Infect 2002;3:315-335.